Medicus Pharma (MDCX) Net Income towards Common Stockholders (2024 - 2025)

Medicus Pharma (MDCX) reported Net Income towards Common Stockholders of -$15.1 million for Q4 2025, down 326.05% on a YoY basis from $6.7 million in Q4 2024, and down 100448813.33% quarter-over-quarter from -$15.0 in Q3 2025.

Medicus Pharma (MDCX) Net Income towards Common Stockholders (2024 - 2025) Analysis & Trends

Medicus Pharma has reported Net Income towards Common Stockholders for 2 years, with the latest figure at -$15.1 million in Q4 2025.

  • For the quarter ending Q4 2025, Net Income towards Common Stockholders fell 326.05% year-over-year to -$15.1 million; the trailing twelve-month figure through Dec 2025 stood at -$26.2 million (down 136.41% YoY), and the FY2025 full-year result was -$47.3 million, down 323.84% from the prior year.
  • Net Income towards Common Stockholders for Q4 2025 stood at -$15.1 million, down from -$15.0 in the prior quarter.
  • The five-year high for Net Income towards Common Stockholders was -$15.0 in Q3 2025, with the low at -$15.1 million in Q4 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn 2.34 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn 7.40 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn 5.24 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn 697.00 Mn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn -4.21 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn 1.82 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn 2.02 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn -13.00 Mn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn 2.68 Bn
10 Medicus Pharma 6.05 Mn 6.15 Mn - -15.07 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -15.07 Mn
Sep 30, 2025 -15.00
Jun 30, 2025 -6.02 Mn
Mar 31, 2025 -5.10 Mn
Dec 31, 2024 -3.54 Mn
Sep 30, 2024 -2.28 Mn
Jun 30, 2024 -3.55 Mn
Mar 31, 2024 -1.71 Mn